A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis

Hepatology ◽  
2020 ◽  
Vol 72 (6) ◽  
pp. 1924-1934 ◽  
Author(s):  
Sonia Alonso López ◽  
María Luisa Manzano ◽  
Francisco Gea ◽  
María Luisa Gutiérrez ◽  
Adriana Maria Ahumada ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Advanced Fibrosis ◽  
Viral Response ◽  
Model Based ◽  
Noninvasive Markers ◽  
Carcinoma Risk

scholarly journals Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?

2021 ◽  
Vol 27 (40) ◽  
pp. 6737-6749
Author(s):  
Adriana Ahumada ◽  
Laura Rayón ◽  
Clara Usón ◽  
Rafael Bañares ◽  
Sonia Alonso Lopez
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Advanced Fibrosis ◽  
Viral Response ◽  
Carcinoma Risk

scholarly journals Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus

2021 ◽  
Author(s):  
Nobuharu Tamaki ◽  
Masayuki Kurosaki ◽  
Yutaka Yasui ◽  
Nami Mori ◽  
Keiji Tsuji ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Risk Assessment ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Advanced Fibrosis ◽  
Carcinoma Risk

scholarly journals Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3414
Author(s):  
Hye Won Lee ◽  
Dai Hoon Han ◽  
Hye Jung Shin ◽  
Jae Seung Lee ◽  
Seung Up Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Direct Acting Antivirals ◽  
Treatment Regimens ◽  
Direct Acting ◽  
Similar Risk ◽  
Carcinoma Risk

By pegylated interferon (PegIFN)-free direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection, a sustained virological response (SVR) rate >95% can be attained with a satisfactory tolerability and shorter treatment duration. However, it remains controversial whether there is any difference in prognosis depending on regimens—PegIFN or DAAs. We compared the probabilities of hepatocellular carcinoma (HCC) development between patients achieving an SVR by PegIFN/ribavirin (PegIFN group, n = 603) and DAAs (DAAs group, n = 479). The DAAs group was significantly older and had a higher proportion of cirrhosis than the PegIFN group. Before adjustment, the DAAs group had a higher HCC incidence than the PegIFN group (p < 0.001). However, by multivariate analyses, the DAAs (vs. PegIFN) group was not associated with HCC risk (adjusted hazard ratio 0.968, 95% confidence interval 0.380–2.468; p = 0.946). Old age, male, higher body mass index, cirrhosis, and lower platelet count were associated with increased HCC risk (all p < 0.05). After propensity score matching (PSM), a similar HCC risk between the two groups was observed (p = 0.372). We also compared HCC incidences according to sofosbuvir (SOF)-based and SOF-free DAAs, showing a similar risk in both groups before adjustment (p = 0.478) and after PSM (p = 0.855). In conclusion, post-SVR HCC risks were comparable according to treatment regimens; PegIFN- vs. DAA-based regimens and SOF-based vs. SOF-free DAA regimens. Further studies with a longer follow-up period are required.

scholarly journals Hepatitis C virus Genotype 1a core gene nucleotide patterns associated with hepatocellular carcinoma risk

2015 ◽  
Vol 96 (9) ◽  
pp. 2928-2937 ◽  
Author(s):  
Brent Korba ◽  
Kirti Shetty ◽  
Alexei Medvedev ◽  
Prasanth Viswanathan ◽  
Rency Varghese ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Core Gene ◽  
Virus Genotype ◽  
Genotype 1A ◽  
Carcinoma Risk

Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk

2018 ◽  
Vol 25 (12) ◽  
pp. 1481-1492 ◽  
Author(s):  
Maryam Darvishian ◽  
Naveed Z. Janjua ◽  
Mei Chong ◽  
Darrel Cook ◽  
Hasina Samji ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Clearance ◽  
The Impact ◽  
Carcinoma Risk
Sign in / Sign up

Export Citation Format

Share Document